Future directions on prophylaxis and therapy of cytomegalovirus diseases

International Journal of Antimicrobial Agents

Volumn 7, Issue 4, 1996, Pages 287-291

  Volpi, Antonio ^a,c   Gentile, Giuseppe ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NONE   (Italy)

Author keywords

cytomegalovirus; pre emptive therapy; transplant patients

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; LOBUCAVIR; VALACICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; GASTROENTERITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL;

EID: 0030268053     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(96)00340-8     Document Type: Conference Paper

References (13)

1. [1] Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994;84:1703-1721.
2. [2] Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991;114:525-531.
3. [3] Li C, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant:correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-1979.
4. [4] Spector SA, McKinley GF, Lalezari JB, et al. Oral ganciclovir for the prevention of Cytomegalovirus disease in persons with AIDS. N Engl J Med 1996;334:1491-1497.
5. [5] Prentice HG, Gluckman E, Powles RL et al. Impact on long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343:749-753.
6. [6] Walter EA, Greenberg PD, Gilbert MA, et al. Reconstitution of cellular immunity against Cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Eng J Med 1995;333:1038-1044.
7. [7] Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992;326:663-667.
8. [8] Boppana SB, Pass R, Britt WJ. Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital infections. J Infect Dis 1993;167:72-77
9. [9] Jonjic S, Pavic I, Polic B, Crnkovic I, Lucin P, Koszinowski UH. Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus, J Exp Med 1994;179:1713-1717.
10. [10] Wittes J, Kelly A, Plante K, et al. CMV Hyperimmune globulin (CMVIG) prevents CMV infection, severe CMV disease and CMV-associated mortality in transplant recipients. 35th Interscience Conf Antimicrobial Agents and Chemotherapy, September 17-20, 1995, San Francisco, California.
11. [11] Paar DP, Pollard RB. Immunotherapy of CMV infections. In: J. Mills et al. (eds.) Antiviral Chemotherapy 4. Plenum Press, New York, 1996, pp. 145-151.
12. [12] Klingbeil CK, Guo J, Dumont LC, et al. Human anti-cytomegalovirus monoclonal antibody (MSL 109), but not CMV hyperimmune globulin, reduced vitreoretinal pathology associated with CMV retinal disease in the rabbit model. 5th Int Cytomegalovirus Conf, Stockholm, May 21-24, 1995, pp. 249.
13. [13] Jacobson MA. Update (1995) on clinical trials of antiviral therapy and prophylaxis for AIDS-related cytomegalovirus disease. Scand J Infect Dis Suppl 1995;99:96-9.